Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics

Kenneth C. Anderson, Ola Landgren, Rebecca C. Arend, Jeffrey Chou, Ira A. Jacobs

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


More oncology biologics are becoming available for subcutaneous (sc.) administration and are expected to provide useful therapeutic options. We evaluated evidence published in the past 5 years to assess the humanistic and economic impact of sc. versus intravenous administration of approved cancer therapies and identify outcomes favoring either administration route. These publications focused predominantly on healthcare resource utilization and economic outcomes, demonstrating resource and cost savings with sc. administration. Patients reported a better health-related quality of life and preference for sc. formulations. Time-and-motion study analyses confirmed the convenience of sc. administration. These findings suggest that future availability of sc. oncology biologics, especially anti-PD-1/PD-ligand 1 antibodies due to their increased utility in various malignancies, may be beneficial for patients, healthcare providers and payers.

Original languageEnglish (US)
Pages (from-to)3267-3281
Number of pages15
JournalFuture Oncology
Issue number28
StatePublished - 2019
Externally publishedYes


  • biologic
  • cancer
  • cost
  • HCRU
  • HRQoL
  • intravenous
  • preference
  • subcutaneous
  • tolerability

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics'. Together they form a unique fingerprint.

Cite this